Shots: ImmuNext to receive $40M upfront, $565M as development & commercialization milestones and royalties on sales of products. Lilly to get an exclusive WW licence to develop & commercialize novel […]readmore
Tags : Chronic Autoimmune Diseases
Biosimilars
Regulatory
Sandoz’s Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment
Shots: The approval is based on the non-inferiority data demonstrating its biosimilarity in terms of PK, immunogenicity and safety meeting all 1Eps & results of ADACCESS study confirming its safety […]readmore